Searching for new drugs to treat Alzheimer’s disease dementia through multiple pathways  

作　　者：Hua Bai Xiao-Feng Feng 

机构地区：[1]Department of Neurology,The Third Affiliated Hospital of Guizhou Medical University,Duyun 558099,Guizhou Province,China [2]Department of Neurology,Wulong Branch of the People's Hospital Affiliated to Chongqing University,Wulong 408500,Chongqing,China [3]Department of Neurology,Guizhou Medical University,Guiyang 550004,Guizhou Province,China

出　　处：《World Journal of Clinical Cases》2025年第1期22-28,共7页世界临床病例杂志（英文）

基　　金：Supported by National Natural Science Foundation of China (General Program),No.32060182;Qiannan Prefecture Science and Technology Plan Project in China,No.Qiannan Kehe She Zi[2022]No.1.

摘　　要：Dementia is a group of diseases,including Alzheimer's disease(AD),vascular dementia,Lewy body dementia,frontotemporal dementia,Parkinson's disease dementia,metabolic dementia and toxic dementia.The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms,nutritional support therapy for repairing nerve cells,psychological auxiliary treatment,and treatment that improves cognitive function through drugs.Among them,drug therapy to improve cognitive function is important.This review focuses on introducing and commenting on some recent progress in exploring drugs to improve cognitive function,especially the new progress in drug treatment for AD.We mainly discuss the opportunities and challenges in finding and developing new therapeutic drugs from the aspects of acetylcholinesterase,N-methyl-D-aspartate glutamate receptor,amyloid protein,tau protein and chronic immune inflammation.

关 键 词：Alzheimer's disease DEMENTIA Cholinesterase inhibitor Beta amyloid Tau protein 

分 类 号：R749.16[医药卫生—神经病学与精神病学]